Karyopharm Therapeutics (KPTI) PT Lowered to $5 at JPMorgan
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $1.99 -1.97%
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
JPMorgan analyst Eric Joseph lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $5.00 (from $6.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Birkenstock Holding plc (BIRK) PT Raised to $44 at Morgan Stanley
- Cellebrite (CLBT) PT Lowered to $15 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
